ACCC 2020 Impact Report
, Vol.36, N.5
, and our video podcast,
CANCER BUZZ TV
Providing a VOICE for the MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS they serve since 1997
Meetings & Education
SCOS Fellows Travel Award
State Society Education Series
Articles and Blogs
Patient Advocacy Organizations
Most Favored Nation Drug Pricing Model
State & Federal Resources
FDA Oncology Drug Approvals
Financial Advocacy & Patient Assistance
Find A Clinical Trial
National Professional Organizations
Off-Label Use Literature
Become a Corporate Member
NEW FDA APPROVALS IN ONCOLOGY: 2020 HIGHLIGHTS
20 novel drugs from 19 different companies were approved for 15 different conditions.
In addition, 2 approvals were for new formulations of already marketed drugs—Onureg
) and Darzalex Faspro
daratumumab and hyaluronidase-fihj
For the first time ever, more than half of the approvals (11) were “accelerated” (i.e., based on intermediate endpoints). Continued approval for these drugs may depend on verification of clinical benefit.
Tyrosine kinase inhibitors constituted the largest single drug “type” (there were 7), while drug conjugates were the 2nd largest modality (4).
Approvals were about evenly divided between oral and infused/injected agents (9 and 11, respectively).
Seven of the approvals specify genetic alterations that should be incorporated into patient selection.